Skip to main content

Table 4 Associations between plasma lnMMP-1, -2, -3, -9 and -10 and lnTIMP-1 and estimated glomerular filtration rate, urinary albumin excretion, low-grade inflammation and endothelial dysfunction

From: Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Model eGFR Ln-UAE LGI ED
β 95% CI p value β 95% CI p value β 95% CI p value β 95% CI p value
MMP-1
 1 −4.15 −6.58; −1.73 0.001 −0.01 −0.13; 0.11 0.912 0.14 0.02; 0.25 0.017 −0.07 −0.18; 0.05 0.249
 2 −2.90 −5.22; −0.57 0.015 −0.03 −0.14; 0.08 0.588 0.11 0.00; 0.22 0.045 −0.12 −0.23; −0.01 0.031
MMP-2
 1 −11.9 −14.27; −9.56 <0.001 0.29 0.16; 0.41 <0.001 −0.02 −0.14; 0.10 0.770 0.06 −0.06; 0.18 0.333
 2 −10.1 −12.48; −7.64 <0.001 0.19 0.07; 0.32 0.002 0.02 −0.11; 0.15 0.759 0.07 −0.06; 0.19 0.318
MMP-3
 1 −12.6 −15.37; −9.92 <0.001 0.28 0.13; 0.42 <0.001 0.02 −0.12; 0.16 0.779 0.02 −0.12; 0.16 0.792
 2 −10.3 −13.05; −7.64 <0.001 0.16 0.02; 0.30 0.022 0.05 −0.09; 0.19 0.513 0.02 −0.12; 0.16 0.818
MMP-9
 1 −0.72 −3.13; 1.70 0.559 0.02 −0.09; 0.14 0.708 0.28 0.18; 0.39 <0.001 0.05 −0.06; 0.16 0.347
 2 −0.14 −2.56; 2.29 0.912 0.02 −0.10; 0.13 0.781 0.22 0.11; 0.33 <0.001 −0.03 −0.15; 0.08 0.580
MMP-10
 1 −6.45 −8.70; −4.19 <0.001 0.08 −0.03; 0.20 0.146 0.14 0.03; 0.25 0.010 0.13 0.03; 0.24 0.015
 2 −6.18 −8.32; −4.03 <0.001 0.11 0.00; 0.21 0.045 0.09 −0.02; 0.19 0.104 0.09 −0.02; 0.19 0.110
TIMP-1
 1 −10.2 −12.65; −7.82 <0.001 0.26 0.14; 0.39 <0.001 0.30 0.19; 0.42 <0.001 0.23 0.11; 0.35 <0.001
 2 −8.13 −10.58; −5.68 <0.001 0.17 0.05; 0.29 0.005 0.33 0.21; 0.45 <0.001 0.22 0.10; 0.34 <0.001
  1. The standardized regression coefficient β represents the difference in eGFR (in ml/min/1.73 m2), lnUAE (in mg/24 h), LGI (in SD) or ED (in SD) per 1 SD increase in lnMMP-1, -2, -3, -9, and -10 and lnTIMP-1
  2. MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
  3. Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
  4. Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline